Tennessee
Requires Coverage of Comprehensive Biomarker Testing
Only for some plans
Highlighted Disparity
Latino individuals in Tennessee are least likely to be diagnosed early
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in Tennessee is 66.0 and significantly higher than the national rate of 52.1.
- It ranks 45th among all states, placing it in the below average tier.
- Over the last five years, the rate of new cases in Tennessee improved by 11%.
- Note: When examining incidence data, it is important to note that the COVID-19 pandemic disrupted access to medical care. This resulted in a drop in cancer diagnoses for the year 2020, particularly for cancers diagnosed before symptoms develop (including lung cancer). This drop reflects changes in medical care for 2020 and should not necessarily be interpreted as a reduction in the underlying cancer burden.
Five-Year Survival Rate:
- The percent of people living five years after being diagnosed with lung cancer (the survival rate) in Tennessee is 27.1%, which is significantly lower than the national rate of 31.0%.
- It ranks 35th among the 43 states with survival data, placing it in the below average tier.
- Over the last five years, the survival rate in Tennessee improved by 22%.
Early Diagnosis:
- In Tennessee, 27.4% of cases are caught at an early stage, which is significantly lower than the national rate of 29.3%.
- It ranks 38th among the 47 states with data on diagnosis at an early stage, placing it in the below average tier.
- Over the last five years, the early diagnosis rate in Tennessee improved by 19%.
Lung Cancer Treatment
Biomarker Coverage:
- Tennessee required some insurance plans to cover comprehensive biomarker testing, including for lung cancer, as of September 2026.
Surgical Treatment:
- Tennessee ranked 36th (out of the 40 states with available data) with 16.6% of cases undergoing surgery as part of the first course of treatment.
- This is significantly lower than the national rate of 21.4% and puts Tennessee in the below average tier.
No Treatment:
- Tennessee ranked 16th (out of the 47 states with available data) with 18.3% of cases not receiving any treatment.
- This is significantly lower than the national rate of 20.9% and puts Tennessee in the above average tier.
Screening
Screening for High Risk:
- The lung cancer screening rate for Tennessee was unavailable in 2024.
Prevention
Tobacco Use:
- The 2025 smoking rate in Tennessee is 15.0% and significantly higher than the national rate of 10.4%.
- It ranks 45th (out of the 48 states with available data), placing it in the bottom tier.
Radon:
- In Tennessee, 26.8% of radon tests results were at or above the action level recommended by EPA.
- It ranks 30th among all states, placing it in the average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 58.2 per 100,000 population among Black individuals in Tennessee, significantly higher than the rate of 53.5 among Black individuals nationally, and significantly lower than the rate of 69.0 among white individuals in Tennessee.
- The five-year survival rate is 27.6% among Black individuals in Tennessee, not significantly different than the rate of 28.5% among Black individuals nationally, and not significantly different than the rate of 26.9% among white individuals in Tennessee.
24.5% of lung cancer cases are diagnosed at an early stage among Black individuals in Tennessee, significantly lower than the rate of 26.3% among Black individuals nationally, and significantly lower than the rate of 28.0% among white individuals in Tennessee.
14.4% of Black individuals with lung cancer in Tennessee underwent surgery, significantly lower than the rate of 17.9% among Black individuals nationally, and significantly lower than the rate of 16.9% among white individuals in Tennessee.
19.3% of Black individuals with lung cancer in Tennessee did not receive any treatment, significantly lower than the rate of 22.7% among Black individuals nationally, and not significantly different than the rate of 18.3% among white individuals in Tennessee.
Latino individuals:
- The rate of new lung cancer cases is 22.8 per 100,000 population among Latino individuals in Tennessee, significantly lower than the rate of 27.8 among Latino individuals nationally, and significantly lower than the rate of 69.0 among white individuals in Tennessee.
State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
21.7% of lung cancer cases are diagnosed at an early stage among Latino individuals in Tennessee, not significantly different than the rate of 24.7% among Latino individuals nationally, and significantly lower than the rate of 28.0% among white individuals in Tennessee.
16.3% of Latino individuals with lung cancer in Tennessee underwent surgery, not significantly different than the rate of 22.0% among Latino individuals nationally, and not significantly different than the rate of 16.9% among white individuals in Tennessee.
13.8% of Latino individuals with lung cancer in Tennessee did not receive any treatment, significantly lower than the rate of 25.1% among Latino individuals nationally, and not significantly different than the rate of 18.3% among white individuals in Tennessee.
Asian or Pacific Islander individuals:
- The rate of new lung cancer cases is 28.8 per 100,000 population among Asian or Pacific Islanders individuals in Tennessee, not significantly different than the rate of 32.7 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 69.0 among white individuals in Tennessee.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
21.3% of lung cancer cases are diagnosed at an early stage among Asian or Pacific Islander individuals in Tennessee, not significantly different than the rate of 24.8% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 28.0% among white individuals in Tennessee.
24.1% of Asian or Pacific Islander individuals with lung cancer in Tennessee underwent surgery, not significantly different than the rate of 26.0% among Asian or Pacific Islander individuals nationally, and significantly higher than the rate of 16.9% among white individuals in Tennessee.
17.2% of Asian or Pacific Islander individuals with lung cancer in Tennessee did not receive any treatment, not significantly different than the rate of 19.1% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 18.3% among white individuals in Tennessee.
Indigenous Peoples:
- The rate of new lung cancer cases is 18.5 per 100,000 population among Indigenous peoples (American Indians/Alaska Natives) in Tennessee, significantly lower than the rate of 38.0 among Indigenous Peoples nationally, and significantly lower than the rate of 69.0 among white individuals in Tennessee.
- State-level survival rates are not available for Indigenous Peoples at this time. Nationally, the five-year survival rate among Indigenous Peoples is 22.3% and not significantly different than the rate of 25.0% among white individuals.
Lung cancer data (including early diagnosis, surgery, lack of treatment) is incomplete or unavailable for Indigenous Peoples (American Indians/Alaska Natives) in Tennessee due to data limitations.
Summary
The early diagnosis rate in Tennessee falls into the below average tier. The state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
Tennessee required some insurance plans to cover comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
Tennessee falls into the above average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: November 10, 2026